Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA)

NCT01215942 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01215942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01215942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of LY2127399 in Patients With Rheumatoid Arthritis (RA)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Terminated
Start date
June 30, 2011
Completion date
February 28, 2014
Enrollment
1,086 (actual)
Sites
327

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis